Neuropathic Pain – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Neuropathic Pain – Pipeline Review, H2 2017’, provides an overview of the Neuropathic Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neuropathic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuropathic Pain and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Neuropathic Pain

The report reviews pipeline therapeutics for Neuropathic Pain by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Neuropathic Pain therapeutics and enlists all their major and minor projects

The report assesses Neuropathic Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Neuropathic Pain

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Neuropathic Pain

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Neuropathic Pain pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

2-BBB Medicines BV

AbbVie Inc

Abide Therapeutics Inc

Acadia Pharmaceuticals Inc

Achelios Therapeutics Inc

Affectis Pharmaceuticals AG

AnaBios Corp

Anavex Life Sciences Corp

AngioChem Inc

Aptinyx Inc

Arena Pharmaceuticals Inc

Astellas Pharma Inc

AstraZeneca Plc

Aucta Pharmaceuticals LLC

BCI Pharma

BCN Peptides SA

Biogen Inc

Bionomics Ltd

Bristol-Myers Squibb Co

Can-Fite BioPharma Ltd

Cara Therapeutics Inc

Celgene Corp

Centrexion Therapeutics Corp

Cerecor Inc

Chromocell Corp

Circuit Therapeutics Inc

Colby Pharmaceutical Co

ConSynance Therapeutics Inc

ContraVir Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Cytogel Pharma LLC

Daewoong Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

Develco Pharma Schweiz AG

Dompe Farmaceutici SpA

Eisai Co Ltd

Eli Lilly and Co

Endece LLC

Evec Inc

Genecode AS

GL Pharm Tech Corp

Glialogix Inc

Grunenthal GmbH

GT Biopharma Inc

GW Pharmaceuticals Plc

Hydra Biosciences Inc

Immune Pharmaceuticals Inc

India Globalization Capital Inc

Intec Pharma Ltd

Integral Molecular Inc

IntelGenx Corp

Intellipharmaceutics International Inc

Ionis Pharmaceuticals Inc

Jeil Pharmaceutical Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Jiangsu Nhwa Pharmaceutical Corp Ltd

JT Pharmaceuticals Inc

Knopp Biosciences LLC

Kolon Life Science Inc

KPI Therapeutics Inc

Lexicon Pharmaceuticals Inc

Lohocla Research Corp

Mapi Pharma Ltd

MD Biosciences GmbH

Medifron DBT Co Ltd

MEDRx Co Ltd

Medy-Tox Inc

Merck & Co Inc

Mitsubishi Tanabe Pharma Corp

Mundipharma International Ltd

Nanomerics Ltd

Neurim Pharmaceuticals Ltd

Neurocentrx Pharma Ltd

NeuroCycle Therapeutics GmbH

NeurOp Inc

Newron Pharmaceuticals SpA

Nippon Chemiphar Co Ltd

Nippon Zoki Pharmaceutical Co Ltd

NoNO Inc

Novartis AG

Novassay SA

Orexigen Therapeutics Inc

Orion Corporation

Patagonia Pharmaceuticals LLC

PeriphaGen Inc

Pfizer Inc

Pharmaleads SA

Phosphagenics Ltd

RaQualia Pharma Inc

Re-Pharm Ltd

Relmada Therapeutics Inc

Revance Therapeutics Inc

Rottapharm Biotech Srl

Saniona AB

Scilex Pharmaceuticals Inc

Shionogi & Co Ltd

Sunovion Pharmaceuticals Inc

Takeda Pharmaceutical Co Ltd

Teva Pharmaceutical Industries Ltd

Theranexus SAS

Toray Industries Inc

Torrent Pharmaceuticals Ltd

Trevena Inc

Vertex Pharmaceuticals Inc

Virobay Inc

VistaGen Therapeutics Inc

Vitality Biopharma Inc

Yooyoung Pharm Co Ltd

Yuhan Corp

Yungjin Pharm Co Ltd

Zynerba Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Neuropathic Pain Overview 8

Neuropathic Pain Therapeutics Development 9

Neuropathic Pain Therapeutics Assessment 36

Neuropathic Pain Companies Involved in Therapeutics Development 53

Neuropathic Pain Drug Profiles 102

Neuropathic Pain Dormant Projects 429

Neuropathic Pain Discontinued Products 447

Neuropathic Pain Product Development Milestones 452

Appendix 463

List of Tables

List of Tables

Number of Products under Development for Neuropathic Pain, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Products under Development by Companies, H2 2017 (Contd..5), H2 2017

Products under Development by Companies, H2 2017 (Contd..6), H2 2017

Products under Development by Companies, H2 2017 (Contd..7), H2 2017

Products under Development by Companies, H2 2017 (Contd..8), H2 2017

Products under Development by Companies, H2 2017 (Contd..9), H2 2017

Products under Development by Companies, H2 2017 (Contd..10), H2 2017

Products under Development by Companies, H2 2017 (Contd..11), H2 2017

Products under Development by Universities/Institutes, H2 2017

Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Neuropathic Pain Pipeline by 2-BBB Medicines BV, H2 2017

Neuropathic Pain Pipeline by AbbVie Inc, H2 2017

Neuropathic Pain Pipeline by Abide Therapeutics Inc, H2 2017

Neuropathic Pain Pipeline by Acadia Pharmaceuticals Inc, H2 2017

Neuropathic Pain Pipeline by Achelios Therapeutics Inc, H2 2017

Neuropathic Pain Pipeline by Affectis Pharmaceuticals AG, H2 2017

Neuropathic Pain Pipeline by AnaBios Corp, H2 2017

Neuropathic Pain Pipeline by Anavex Life Sciences Corp, H2 2017

Neuropathic Pain Pipeline by AngioChem Inc, H2 2017

Neuropathic Pain Pipeline by Aptinyx Inc, H2 2017

Neuropathic Pain Pipeline by Arena Pharmaceuticals Inc, H2 2017

Neuropathic Pain Pipeline by Astellas Pharma Inc, H2 2017

Neuropathic Pain Pipeline by AstraZeneca Plc, H2 2017

Neuropathic Pain Pipeline by Aucta Pharmaceuticals LLC, H2 2017

Neuropathic Pain Pipeline by BCI Pharma, H2 2017

Neuropathic Pain Pipeline by BCN Peptides SA, H2 2017

Neuropathic Pain Pipeline by Biogen Inc, H2 2017

Neuropathic Pain Pipeline by Bionomics Ltd, H2 2017

Neuropathic Pain Pipeline by Bristol-Myers Squibb Co, H2 2017

Neuropathic Pain Pipeline by Can-Fite BioPharma Ltd, H2 2017

Neuropathic Pain Pipeline by Cara Therapeutics Inc, H2 2017

Neuropathic Pain Pipeline by Celgene Corp, H2 2017

Neuropathic Pain Pipeline by Centrexion Therapeutics Corp, H2 2017

Neuropathic Pain Pipeline by Cerecor Inc, H2 2017

Neuropathic Pain Pipeline by Chromocell Corp, H2 2017

Neuropathic Pain Pipeline by Circuit Therapeutics Inc, H2 2017

Neuropathic Pain Pipeline by Colby Pharmaceutical Co, H2 2017

Neuropathic Pain Pipeline by ConSynance Therapeutics Inc, H2 2017

Neuropathic Pain Pipeline by ContraVir Pharmaceuticals Inc, H2 2017

Neuropathic Pain Pipeline by Crinetics Pharmaceuticals Inc, H2 2017

Neuropathic Pain Pipeline by Cytogel Pharma LLC, H2 2017

Neuropathic Pain Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017

Neuropathic Pain Pipeline by Daiichi Sankyo Co Ltd, H2 2017

Neuropathic Pain Pipeline by Develco Pharma Schweiz AG, H2 2017

Neuropathic Pain Pipeline by Dompe Farmaceutici SpA, H2 2017

Neuropathic Pain Pipeline by Eisai Co Ltd, H2 2017

List of Figures

List of Figures

Number of Products under Development for Neuropathic Pain, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Top 10 Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports